OS Therapies Inc — Investor Relations & Filings
Filings indexed
200
across all filing types
Latest filing
2026-05-18
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
OSTX
OS Therapies Inc. is a clinical-stage cancer immunotherapy company focused on developing treatments for cancers that express the HER2 protein. The company's approach is to activate the patient's immune system to target and destroy tumor cells. Its lead candidate, OST-HER2, is a therapeutic vaccine initially being developed for osteosarcoma, a type of bone cancer with a significant unmet medical need. The company plans to expand the development of its technology to other HER2-positive solid tumors, including breast, colorectal, esophageal, lung, and ovarian cancers. The pipeline also includes proprietary technologies like OST-tADC Tunable Drug Conjugates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-18 | English | |
| 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | |
| 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46383305 | QUARTERLY REPORT | 2026-05-18 | English | ||
| 33196663 | 424B5 - OS Therapies Inc (0001795091) (Filer) | 2026-04-02 | English | ||
| 32898412 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898413 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898414 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898415 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898416 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898417 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 32898418 | 4 - OS THERAPIES INC (0001795091) (Filer) | 2026-02-13 | English | ||
| 31749726 | 4 Filing | 2026-02-13 | English | ||
| 31749645 | 8-K Filing | 2026-02-13 | English | ||
| 13219850 | Regulatory Filings 2026 | 2026-01-20 | English | ||
| 13219851 | CURRENT REPORT | 2026-01-12 | English | ||
|
2025
2 filings
| |||||
| 13219852 | Director's Dealing 2025 | 2025-12-20 | English | ||
| 13219853 | Director's Dealing 2025 | 2025-12-20 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alpha Tau Medical Ltd.
Clinical-stage oncology firm developing alpha radiation the…
|
DRTS | US | Professional, scientific and te… |
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
OS Therapies Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34454/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34454 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34454 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34454 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34454}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OS Therapies Inc (id: 34454)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.